Merrimack Pharma (MACK) Reports Q4 Loss of $0.89
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Merrimack Pharmaceuticals (MACK) PT Lowered to $12 at Baird
March 12, 2018 11:10 AM EDTBaird lowered its price target on Merrimack Pharmaceuticals (NASDAQ: MACK) to $12.00 (from $15.00) while maintaining a Neutral rating.
Analsyt Michael Ulz said while multiple readouts are expected later this year, they are incrementally cautious and reiterate our Neutral rating.
... More